EP1983051A2 - Isolation et purification de molécules d'acide nucléique avec une phase solide - Google Patents
Isolation et purification de molécules d'acide nucléique avec une phase solide Download PDFInfo
- Publication number
- EP1983051A2 EP1983051A2 EP08007550A EP08007550A EP1983051A2 EP 1983051 A2 EP1983051 A2 EP 1983051A2 EP 08007550 A EP08007550 A EP 08007550A EP 08007550 A EP08007550 A EP 08007550A EP 1983051 A2 EP1983051 A2 EP 1983051A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- solid phase
- group
- ionic liquid
- carbon atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 156
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 155
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 155
- 239000007790 solid phase Substances 0.000 title claims abstract description 102
- 238000002955 isolation Methods 0.000 title abstract description 13
- 238000000746 purification Methods 0.000 title description 9
- 239000002608 ionic liquid Substances 0.000 claims abstract description 53
- 238000001179 sorption measurement Methods 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 51
- 229910052757 nitrogen Inorganic materials 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 51
- 230000003196 chaotropic effect Effects 0.000 claims description 37
- 239000000523 sample Substances 0.000 claims description 37
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 239000000463 material Substances 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 33
- -1 butylmethylimidazolium cation Chemical class 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 229910052727 yttrium Inorganic materials 0.000 claims description 21
- 150000002892 organic cations Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- 125000000524 functional group Chemical group 0.000 claims description 15
- 239000012062 aqueous buffer Substances 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 230000003993 interaction Effects 0.000 claims description 8
- 229920002477 rna polymer Polymers 0.000 claims description 7
- IQQRAVYLUAZUGX-UHFFFAOYSA-N 1-butyl-3-methylimidazolium Chemical compound CCCCN1C=C[N+](C)=C1 IQQRAVYLUAZUGX-UHFFFAOYSA-N 0.000 claims description 6
- REACWASHYHDPSQ-UHFFFAOYSA-N 1-butylpyridin-1-ium Chemical compound CCCC[N+]1=CC=CC=C1 REACWASHYHDPSQ-UHFFFAOYSA-N 0.000 claims description 3
- NJMWOUFKYKNWDW-UHFFFAOYSA-N 1-ethyl-3-methylimidazolium Chemical compound CCN1C=C[N+](C)=C1 NJMWOUFKYKNWDW-UHFFFAOYSA-N 0.000 claims description 3
- CGWBIHLHAGNJCX-UHFFFAOYSA-N 2-butylguanidine Chemical compound CCCCNC(N)=N CGWBIHLHAGNJCX-UHFFFAOYSA-N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 59
- 108020004414 DNA Proteins 0.000 description 51
- 239000011521 glass Substances 0.000 description 46
- 239000002245 particle Substances 0.000 description 35
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical class NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 26
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 239000000872 buffer Substances 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 19
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 244000309466 calf Species 0.000 description 11
- 230000005291 magnetic effect Effects 0.000 description 11
- 210000001541 thymus gland Anatomy 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 10
- 235000012239 silicon dioxide Nutrition 0.000 description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 229940094991 herring sperm dna Drugs 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000010453 quartz Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000006249 magnetic particle Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- PBWYKHZQEJXPAA-UHFFFAOYSA-N 2-butylguanidine;hydrochloride Chemical compound Cl.CCCCN=C(N)N PBWYKHZQEJXPAA-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 2
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SADCIRLPBJDLBS-UHFFFAOYSA-M 1-butyl-3-methylimidazol-3-ium;2-methoxyethyl sulfate Chemical compound COCCOS([O-])(=O)=O.CCCCN1C=C[N+](C)=C1 SADCIRLPBJDLBS-UHFFFAOYSA-M 0.000 description 1
- KIDIBVPFLKLKAH-UHFFFAOYSA-M 1-butyl-3-methylimidazol-3-ium;octyl sulfate Chemical compound CCCCN1C=C[N+](C)=C1.CCCCCCCCOS([O-])(=O)=O KIDIBVPFLKLKAH-UHFFFAOYSA-M 0.000 description 1
- SIXHYMZEOJSYQH-UHFFFAOYSA-M 1-butyl-3-methylimidazol-3-ium;thiocyanate Chemical compound [S-]C#N.CCCCN1C=C[N+](C)=C1 SIXHYMZEOJSYQH-UHFFFAOYSA-M 0.000 description 1
- POKOASTYJWUQJG-UHFFFAOYSA-M 1-butylpyridin-1-ium;chloride Chemical compound [Cl-].CCCC[N+]1=CC=CC=C1 POKOASTYJWUQJG-UHFFFAOYSA-M 0.000 description 1
- VRFOKYHDLYBVAL-UHFFFAOYSA-M 1-ethyl-3-methylimidazol-3-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCN1C=C[N+](C)=C1 VRFOKYHDLYBVAL-UHFFFAOYSA-M 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical group C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000012494 Quartz wool Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229910008051 Si-OH Inorganic materials 0.000 description 1
- 229910006358 Si—OH Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- JIONSDIFUGDYLD-UHFFFAOYSA-N diaminomethylideneazanium;phenol;thiocyanate Chemical compound [S-]C#N.NC([NH3+])=N.OC1=CC=CC=C1 JIONSDIFUGDYLD-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004693 imidazolium salts Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000001282 organosilanes Chemical class 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
Definitions
- the present invention relates to the filed of nucleic acid isolation and purification.
- a method and a kit for the isolation of nucleic acid from sample material are provided.
- the present invention is directed to methods and kits for obtaining a nucleic acid in a form that is substantially free from concomitant substances.
- the isolated nucleic acid is suitable for applications of molecular biology.
- the method of the invention includes adsorbing (i.e. reversibly binding) the nucleic acid to a solid phase, optionally washing the solid phase with the adsorbed nucleic acid, and eluting the nucleic acid from the solid phase.
- nucleic acids are often present in very small concentrations and, on the other hand, they are often found in the presence of many other solid and dissolved substances, e.g. after lysis of cells or in sample material from food, they are difficult to isolate or to measure, in particular in biospecific assays which allow the detection of specific analytes. Therefore, in the majority of cases, these microbiological tests comprise at least one amplification step of the characteristic DNA molecules to be detected.
- a well-known assay which entails the selective binding of two oligonucleotide primers is the polymerase chain reaction (PCR) described in US 4,683,195 .
- This method allows the selective amplification of a specific nucleic acid region to detectable levels by a thermostable polymerase in the presence of deoxynucleotide triphosphates in several cycles.
- the PCR technology is a very sensitive technology with respect to both the required amount and the purity of the employed sample material.
- Ligase Chain Reaction (LCR, Wu, D., Y., and Wallace, R., B., Genomics 4 (1989) 560-569 and Barany, F., Proc. Natl. Acad. Sci. USA 88 (1991) 189-193 ); Polymerase Ligase Chain Reaction ( Barany, F., PCR Methods and Appl. 1 (1991) 5-16 ); Gap-LCR ( PCT Patent Publication No. WO 90/01069 ); Repair Chain Reaction ( EP 0 439 182 ), 3SR (Kwoh, D., Y., et al., Proc. Natl. Acad. Sci.
- Ligase Chain Reaction (LCR, Wu, D., Y., and Wallace, R., B., Genomics 4 (1989) 560-569 and Barany, F., Proc. Natl. Acad. Sci. USA 88 (1991) 189-193 ); Polymerase Ligase Chain Reaction ( Barany,
- nucleic acids are only present within the cells of prokaryotic and eukaryotic organisms the cell wall has to be lysed prior to nucleic acid isolation. Concomitantly with the release of the nucleic acid from the cells, all other cellular components are also liberated. This includes proteins, salts, secondary metabolites as well as degradating enzyme, as e.g. proteases and nucleases. These enzymes start to degrade their target immediately. Thus the activity of these degrading enzymes has to be suppressed. This can be achieved by the addition of organic solvents or denaturating agents to the lysis solution. An alternative is the addition of protease and/ or nuclease inhibitors.
- nucleic acids In order to isolate nucleic acids from sample material there are several methods for the extraction of nucleic acids such as sequence-dependent or biospecific methods (e.g. affinity chromatography, hybridisation to immobilised probes) and sequence-independent or physico-chemical methods.
- sequence-dependent or biospecific methods e.g. affinity chromatography, hybridisation to immobilised probes
- sequence-independent or physico-chemical methods e.g.
- cationic surfaces are used to isolate nucleic acids. Such surfaces may be used to adsorb charged DNA molecules, whereby e.g. EP 0 281 390 describes a polycationic support for nucleic acid isolation, WO 01/94573 charged membranes or WO 00/69872 a pH dependent ion exchange matrix.
- WO 02/48164 discloses polymers with switchable charge on solid supports for reversible binding of DNA. Similar to cationic surfaces, polycationic entities have certain DNA-binding affinity, too. Stewart, K., D., et al., J. Phys. Org. Chem. 5 (1992) 461-466 reports an increasing affinity of polyamines in solution for binding to DNA with increasing cationic charge. Doré, K., et al, J. Am. Chem. Soc. 126 (2004) 4240-4244 describes the selectivity of cationic compounds between double-stranded and single-stranded nucleic acids.
- nucleic acid binding materials are glass surfaces due to their ability to reversibly bind DNA in the presence of chaotropic reagents and/ or alcoholic additives ( Vogelstein, B., and Gillespie, D., Proc. Natl. Acad. Sci. USA 76 (1979) 615-619 ). Such binding is assumed to be effected by oxidic surfaces ("X-OH") interacting with phosphate groups of the nucleic acids.
- X-OH oxidic surfaces
- Boom, R., et al., J. Clin. Microbiol. 28 (1990) 495-503 describes a small scale protocol for the purification of DNA and RNA from sample material.
- the method is based on the lysing and nuclease-inactivating properties of a chaotropic agent in the presence of an EDTA/detergent mixture and the nucleic acid-binding properties of silica particles.
- Lithium salts of nucleic acids are known to have a reduced solubility in aqueous solutions.
- European Patent Application EP 0 818 461 a method for the isolation of ribonucleic acid with an acidic solution containing a lithium salt and a chaotropic agent as well as an nucleic acid-binding partner such as silica particles is described.
- compositions for isolating nucleic acids from cells are described.
- the compositions are mixtures of silica gel and glass particles combined with chaotropic salts.
- WO 99/61603 a method for separating and/or isolating circular nucleic acids under alkaline conditions at a pH > 8 with a solid matrix consisting essentially of a silica material in presence of at least one chaotropic substance is described.
- US Patent Application 2004/0121336 describes a method of binding a predetermined amount of a nucleic acid to a multiplicity of solid substrate binding units. A method for gently lysing and solubilizing cells is described in US patent application 2004/0180445 .
- a particular object of the invention is to provide alternative compounds to promote the adsorption of a nucleic acid to a solid substrate.
- the subject matter of the present invention is to provide further compositions and methods to adsorb a nucleic acid to a solid phase.
- the particular use of such compositions and methods is the isolation and purification of nucleic acid molecules.
- a first aspect of the invention is a liquid composition for adsorbing a nucleic acid to a solid phase, characterized in that the composition comprises (a) a salt which is a liquid at room temperature (ionic liquid) and which comprises an organic cation of Formula I whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group; and (b) an aqueous buffer.
- a salt which is a liquid at room temperature (ionic liquid) and which comprises an organic cation of Formula I whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extend
- a further aspect of the invention is the use of a water-soluble ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group; for adsorbing a nucleic acid to a solid phase.
- a further aspect of the invention is a method to enhance the effect of a chaotropic compound on the interaction of a nucleic acid and a solid phase, whereby the nucleic acid is present in a solution comprising an aqueous buffer and a chaotropic agent, characterized in that an effective amount of an ionic liquid is added to the adsorption solution, whereby the ionic liquid comprises an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group, and whereby the ionic liquid enhances adsorption of the nucleic acid to a solid phase.
- a further aspect of the invention is a method for isolating a nucleic acid, comprising the following steps (a) providing the following components: (i.) a solid phase capable of reversibly binding nucleic acids; (ii.) sample material containing the nucleic acid; (iii.) a solution containing an ionic liquid comprising an organic cation of Formula I whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group; (iv.) an aqueous buffer; (b) contacting the provided components under conditions suitable for adsorbing the nucleic acid to the solid phase; (c) separating the solid phase with the adsorbed nucleic acid from the solution; (d) eluting the nucleic acid from the solid phase.
- a further aspect of the invention is a method for adsorbing RNA to a solid phase, characterized in that the method comprises (a) providing the following components: (i.) a solid phase capable of reversibly binding nucleic acids; (ii.) a sample material containing the ribonucleic acid; (iii.) an aqueous solution containing a butylmethylimidazolium cation at a concentration from 1 M to 3 M; and (b) contacting the provided components under conditions suitable for adsorbing the ribonucleic acid to the solid phase.
- a further aspect of the invention is a kit for isolating nucleic acid from nucleic acid containing material, characterized in that the kit comprises (a) a solid phase capable of reversibly binding nucleic acids; (b) an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group.
- a solid phase capable of reversibly binding nucleic acids
- an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge
- the present invention provides new compositions and methods for the purification of nucleic acids. Certain terms are used with particular meaning, or are defined for the first time, in this description of the present invention. For the purposes of the present invention, the terms used are defined by their art-accepted definitions, when such exist, except that when those definitions conflict or partially conflict with the definitions set forth below. In the event of a conflict in definition, the meaning of a terms is first defined by any of the definitions set forth below.
- a and “an” are used herein to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article.
- a compound means one compound or more than one compound.
- a range of numerical values such as a concentration range
- the range is indicated by the word "between”, followed by a first value n1 and a second value n2.
- the lower boundary of the designated range is understood as being the value equal to or higher than the first value.
- the higher boundary of the designated range is understood as being the value equal to or lower than the second value.
- a value x the designated range is given by n1 ⁇ x ⁇ n2.
- n indicates a value x in the interval given by the numerical value ⁇ 5% of the value, i.e. n - 0.05 *n ⁇ x ⁇ n + 0.05 * n.
- the value of n is most preferred, if not indicated otherwise.
- solid phase to which a nucleic acid is adsorbed is understood as being a substrate which is insoluble in the compositions according to the invention.
- a preferred solid phase is a substrate with a surface capable of interacting with the phosphate groups of the backbone of nucleic acids.
- the solid phase may be in the form of porous or non-porous particles, powdered particles, or fibers.
- a solid phase consisting of fleece material which comprises a plurality of non-woven fibers is also encompassed.
- Preferred solid phases consist of glass.
- Preferred solid phases are porous or non-porous mineral substrates such as silica, quartz, celites or other materials with oxidic surfaces (including, e.g.
- solid phase encompasses magnetically attractable particles coated with silica, glass, quartz, or celites.
- a substrate in the form of “powder” or “powdered” material refers to finely divided material which, when dispersed in a liquid composition according to the invention, produces a suspension.
- the term “powder” or “powdered” material is intended to include tablets, in which the powdered material has been aggregated, but still yields a suspension when combined with a liquid phase.
- silica denotes materials which are mainly build up of silicon and oxygen. These materials comprise silica, silicon dioxide, silica gel, fumed silica gel, diatomaceous earth, celite, talc, quartz, glass, glass particles including all different shapes of these materials. Glass particles, for example, may comprise particles of crystalline silica, soda-lime glasses, borosilicate glasses, and fibrous, non-woven glass.
- magnetic particle denotes a particle with paramagnetic or superparamagnetic properties. That is to say, the particle is magnetically displaceable but does not retain any magnetisation in the absence of an externally applied magnetic field.
- sample refers to a complex sample, more preferred a biological sample.
- a complex sample may contain a plurality of organic and inorganic compounds which are desired to be separated from the nucleic acid.
- sample also encompasses an aqueous solution containing nucleic acids derived from other origins, e.g. from chemical or enzymatic reaction mixtures, or from a previous purification of biological sample material.
- biological sample from which nucleic acids are purified, encompasses samples comprising viruses or bacterial cells, as well as isolated cells from multicellular organisms such as human and animal cells as well as tissues and cell cultures.
- the sample can contain leucocytes, and other immunologically active cells, chemical compounds with a low and/ or a high molecular weight such as haptens, antigens, antibodies and nucleic acids.
- the sample can be whole blood, blood serum, blood plasma, cerebral fluid, sputum, stool, biopsy specimens, bone marrow, oral rinses, tissues, urine or mixtures thereof.
- the present invention also encompasses biological samples such as a fluid from the human or animal body; preferably the biological sample is blood, blood plasma, blood serum or urine.
- the blood plasma is preferably EDTA, heparin or citrate blood plasma.
- the biological sample comprises bacterial cells, eukaryotic cells, viruses or mixtures thereof.
- biological sample Also encompassed by the term "biological sample” are cells from plants, and fungi as well as single cell organisms.
- a preferred sample according to the invention is a lysate.
- a "lysate” or a “lysed sample” can be obtained from a complex sample and/ or biological sample material comprising tissue, cells, bacteria or viruses, whereby the structural integrity of the material is disrupted.
- tissue or, more generally, from the particles which make up a biological sample the material may be treated with enzymes or with chemicals to dissolve, degrade or denature the cellular walls and cellular membranes of such organisms. This process is encompassed by the term "lysis”. It is common to use chaotropic agents such as a guanidine salt and/ or anionic, cationic, zwitterionic or non-ionic detergent when nucleic acids are set free in the lysis process.
- the particulate matter is usually separated from the lysate to result in a cleared lysate. This can be done, e.g., by way of filtering or centrifugation. In such a case the cleared lysate is processed further, e.g. by a method according to the invention.
- the term "lysed sample” encompasses a cleared lysate.
- a “chaotropic agent” is any chemical substance which disturbs the ordered structure of liquid water.
- a chaotropic agent also facilitates unfolding, extension and dissociation of proteins ( Dandliker, W., B., and de Saussure, V., A., In: The Chemistry of Biosurfaces, Hair, M., L., ed., Marcel Dekker, Inc. New York (1971) p. 18 ).
- Preferred chaotropic salts are sodium iodide, sodium perchlorate, guanidinium thiocyanate, guanidinium isothiocyanate or guanidinium hydrochloride.
- Another preferred chaotropic agent is urea.
- aqueous aqueous phase and “aqueous” solution describe a liquid phase of which the solvent portion comprises water.
- other solvents such as a water-miscible organic solvent can be present in the solvent portion, too.
- a solution is considered “aqueous” when between 30% and 100%, measured as volume by volume [v/v], of the solvent portion is water.
- nucleic acid denotes DNA and RNA polynucleotides of natural and synthetic origin. This includes modified nucleotides as e.g. dideoxyribonucleotides, nucleobases with modified sugar residues and nucleobases with modified base moieties (see e.g. Scheit, K., H., Nucleotide Analogs, John Wiley and Sons, N.Y. (1980 ); Uhlmann, E., and Peyman, A., Chem. Rev. 90 (1990) 543-584 ). In particular genomic DNA, complementary DNA (cDNA), messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA) and micro RNA (miRNA) is included.
- cDNA complementary DNA
- mRNA messenger RNA
- tRNA transfer RNA
- rRNA ribosomal RNA
- miRNA micro RNA
- an “ionic liquid” is a liquid that contains only ions. In the broad sense, this term includes all the molten salts, for instance, sodium chloride at temperatures higher than 800 °C. However, in this document the term “ionic liquid” is used for salts whose melting point is relatively low. In the context of the present invention the term “ionic liquid” means a salt that is a liquid at room temperature. In addition, the ionic liquid according to the invention is a water-soluble ionic liquid. The "ionic liquid” at the same time denotes a salt composed of a cation and an anion.
- the anion can be an anorganic or organic anion , the cation is mostly an organic cation, but in any case one ion (anion or cation) is an organic ion.
- the cation may comprise imidazolium cations, pyridinium cations, ammonium cations, phosphonium cations and substituted guanidinium cations. At least one ion of the ion pair has a delocalized charge. Due to the weak interactions between both ions, these ionic liquids display a low melting point.
- adsorption generally means adhere or attach molecules or ions (the “solute")to outer surfaces or interfaces so as to increase the concentration of a solute in the vicinity of a solid surface, over that in the bulk of the solution, due to the attractive interaction between the solid immersed into the solution and the solute.
- the binding to the surface is usually weak and reversible. It is a surface process such that the accumulating molecules do not actually penetrate the substance on which they are formed. The term is not to be confused with absorption which means the filling of pores in a solid.
- nucleic acids isolation and purification of nucleic acids is often linked with the use of chaotropic agents like guanidinium salts in high concentrations for adsorbing the nucleic acids to solid phases such as silica matrices ( Vogelstein, B., and Gillespie, D., Proc. Natl. Acad. Sci. USA 76 (1979) 615-619 ; Marko, M., A., et al., Anal. Biochem. 121 (1982) 382-387 ).
- chaotropic salts examples include guanidinium salts such as guanidinium thiocyanate, guanidinium isothiocyanate or guanidinium hydrochloride but also sodium iodide, sodium perchlorate. Other compounds known to the skilled artisan are also possible.
- a chaotropic substance effects removal of water molecules from the hydrate shell of dissolved nucleic acid molecules as well as from the surface of the solid phase, e.g. a silica matrix.
- the described chaotropic effect is accompanied by an increase of the entropy.
- the equilibrium is shifted to the binding of the nucleic acid to the surface of the solid phase.
- the surface of the solid phase has to be in a neutral state.
- the preferred pH range for adsorbing the nucleic acid is between pH 4 and pH 6.
- Additives, e.g. other elements as boron, iron, phosphor, aluminum and the like, present in the silica matrix may shift the appropriate conditions.
- the chaotropic effect can be enhanced by the addition of other dehydrating substances. For example, addition of an organic solvent, e.g. an alcohol, results in an improved adsorption of nucleic acids to glass surfaces.
- the inventors could show that certain ionic liquids efficiently promote the adsorption of nucleic acids from an aequous solution to a solid phase.
- a first aspect of the current invention therefore is a liquid composition for adsorbing a nucleic acid to a solid phase, characterized in that the composition comprises (a) an ionic liquid comprising an organic cation of Formula I whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group; and (b) an aqueous buffer.
- an ionic liquid comprising an organic cation of Formula I whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group.
- Another embodiment of the invention is the use of an ionic liquid comprising an organic cation of Formula I and as defined above for adsorbing a nucleic acid to a solid phase.
- the composition according to the invention which additionally contains a nucleic acid is also referred to as an "adsorption solution" because the composition provides conditions necessary for adsorbing the nucleic acid to a solid phase.
- Y and X are nitrogen atoms and the delocalized positive charge extends over the components Y, X, and N of Formula I.
- the core of the ionic liquid can be a guanidinium residue which carries a positive charge of the cation.
- At least one of the components Y, N, and X additionally carries a further substituent.
- a preferred substituent is selected from the group consisting of a halogen-, an alkyl-, a hydroxyalkyl-, an alkoxyalkyl- and a phenoxyalkyl-function.
- the cation of the ionic liquid is selected from the group consisting of N-(1-butyl)-guanidinium, N-1-(2-methoxyethyl)-guanidinium , and n-butane-1,4-diguanidinium.
- diguanidinium compound a positive charge can be present on either guanidinium group, or on both.
- X is a carbon atom
- Y is a nitrogen atom
- Y and N are part of a cyclic system with conjugated double bonds and the delocalized charge extends over Y and N.
- ionic liquids with such a core are compounds with a pyridinium or an imidazolium moiety. Particular examples therefor are benzimidazolium moieties.
- at least one of the components Y, N, and X additionally carries a further substituent.
- a preferred substituent is selected from the group consisting of an alkyl-, a hydroxyalkyl-, an alkoxyalkyl- and a phenoxyalkyl-function.
- the cation of the ionic liquid is selected from the group consisting of 1-ethyl-3-methyl imidazolium , 1-butyl-3-methyl-imidazolium, 3-methyl-1-[4-(3-methyl-3-H-benzimidazol-1-ium)-but-1-yl]-3H-benzimidazolium-di(toluylsulfat), and 1-butyl-pyridinium.
- Ionic liquids according to the invention are capable of promoting the adsorption of a nucleic acid to a solid phase, preferably a solid phase with a silica surface, and preferably under acidic conditions without the further need of a chaotropic substance such as a guanidinium salt (e.g. guanidinium hydrochloride, guanidinium thiocyanate, guanidinium isothiocyanate).
- a chaotropic substance can be of great advantage in further promoting adsorption.
- adsorption of a nucleic acid to a solid phase can be enhanced by the addition of a compound comprising a butylmethylimidazolium cation to an adsorption solution comprising a conventional chaotropic agent (e.g. Example 2, experiment No. 5, also see Figure 1 ).
- a further embodiment of the invention is a method to enhance the effect of a chaotropic compound on the interaction of a nucleic acid and a solid phase, whereby the nucleic acid is present in a solution comprising an aqueous buffer and a chaotropic agent, characterized in that an effective amount of an ionic liquid is added to the adsorption solution, whereby the ionic liquid comprises an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group, and whereby the ionic liquid enhances adsorption of the nucleic acid to a solid phase.
- the composition additionally contains a chaotropic substance.
- the chaotropic substance is a guanidinium salt.
- Preferred guanidinium salts are guanidinium hydrochloride (guanidinium HCl, Gu-HCl), guanidinium thiocyanate, and guanidinium isothiocyanate.
- a further effect of chaotropic agents is the inhibition of nucleic acid degrading enzymes present during the isolation of the nucleic acid. Additionally reducing agents like dithiotreitol (DTT) may be added.
- DTT dithiotreitol
- For cell lysis detergents are added, e.g. 20 % (w/w) of Triton X-100.
- the detergent also has an influence on the binding characteristics of nucleic acids to the solid phase.
- the agents used for adsorbing nucleic acids to a solid phase need to provide good and selective binding conditions.
- concomitant polypeptides and proteins have to be removed. This can be done for example by an enzymatic digestion with proteinase K. However, some proteolytic enzymes do not work properly at high concentrations of chaotropic agents.
- Herring sperm DNA is composed of high and low molecular weight DNA.
- the surprising result for binding of herring sperm DNA to glass fleece is shown in Figure 1 . It can be seen that the amount of bound DNA varies, depending on the conditions for adsorption and the ionic liquid used. Very good adsorption to the solid phase (two different silica matrices were used) was achieved using 3 M butylmethylimidazolium at pH 4.5.
- the preferred solid phase to which the nucleic acid is adsorbed using the compositions and methods according to the invention comprises a porous or non-porous solid substrate.
- a silica substrate is selected from the group consisting of silica gel, glass fibers, quartz fibers, and celites.
- the solid phase comprises a porous or non-porous mineral substrate selected from the group consisting of metal oxides, and/ or metal mixed oxides, alumina, titania, zirconia, and materials predominantly consisting of glass.
- the solid phase has a particle size of 0.1 ⁇ m to 100 ⁇ m. It is also preferred that porous solid phase materials, when employed, have a pore size of from 2 to 1,000 nm. More preferred, porous or non-porous solid phase materials, especially celites, are in the form of loose packings. Even more preferred, the solid phase consists of filter sheets in the form of glass, quartz or ceramic filter sheets, and/ or a membrane containing silica gel and/ or particles or fibers of mineral substrates and fabrics of quartz or glass wool, that is to say fibrous, non-woven glass.
- the solid phase comprises magnetically attractable particles.
- the magnetically attractable particles are coated with a mineral substrate selected from the group consisting of silica, glass, quartz, and celites. Even more preferred, the substrate comprises magnetically attractable particles coated with glass.
- the magnetic glass particles used in the present invention may be provided in different formulations. It is possible to provide them in the form of a tablet, as a powder or as a suspension. Very much preferred, the magnetic glass particles are suspended in a liquid composition according to the invention. Preferably, these suspensions contain between 5 to 100 mg/ml magnetic glass particles (MGPs).
- the silica-containing material is suspended in aqueous buffered solutions which may optionally contain an ionic liquid according to the invention.
- compositions according to the invention further increase the adsorption of a nucleic acid from an aequous solution to the solid phase. It is preferred that the composition of the invention additionally contains a compound selected from the group consisting of magnesium(II)chloride, and imidazole.
- the procedure of adsorbing a (at least one) nucleic acid to a substrate such as, e.g., glass particles can be described as follows.
- the method for adsorbing a nucleic acid to the solid phase comprises the steps of (a) providing the following components: (i) a solid phase capable of reversibly binding nucleic acids; (ii) sample material containing the nucleic acid; (iii) a composition according to the invention; and (b) contacting the provided components under conditions suitable for adsorbing the nucleic acid to the solid phase.
- the sample material is preferably homogenized in the composition of step (iii) when step (b) is performed.
- the sample material may comprise biological material.
- a homogenization step is performed before step (b). If necessary, after homogenization residual particulate matter such as cell debris is separated from the remaining homogenized sample material by centrifugation and the supernatant is further processed by executing step (b).
- Alternative separation techniques are known, apart from centrifugation, including filtration.
- the procedure of adsorbing the nucleic acid is performed in the presence of an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group.
- an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group.
- the cation of the ionic liquid is selected from the group consisting of N-(1-butyl)-guanidinium, N-1-(2-methoxyethyl)-guanidinium , n-butane-1,4-diguanidinium, 1-ethyl-3-methyl imidazolium , 1-butyl-3-methyl-imidazolium, 3-methyl-1-[4-(3-methyl-3-H-benzimidazol-1-ium)-but-1-yl]-3H-benzimidazoliumdi(toluylsulfat), and 1-butyl-pyridinium.
- the concentration of the ionic liquid in the composition according to the invention is in the range between 0.02 M and 4 M. More preferred, the concentration is between 0.03 M and 3 M.
- contacting the solid phase with the nucleic acid in the presence of a composition according to the invention is performed in a pH range between pH 4.0 and pH 8.0. Acidic conditions are more preferred. This means that in this more preferred embodiment the adsoption process takes place at a pH below 7 and above 4, preferably between pH 4.5 and pH 6.5, most preferred at pH 6. It is obvious for the skilled person to produce suitable aqueous buffered solutions. Buffer systems which suitable for molecular biology purposes may be found e.g. in Sambrook, J., et al., Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press (2001) Cold Spring Harbor, New York .
- Preferred buffer substances are Tris-(hydroxymethyl)-aminomethane (TRIS), 2-morpholinoethanesulfonic acid (MES) phosphate, N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), acetate, salts thereof, and other suitable substances.
- the purification effect results from the behavior of DNA or RNA to bind to material of the solid phase under these conditions, i.e. in the presence of the compositions according to the invention.
- the sample is mixed with the material and incubated for a period of time sufficient for the binding to occur.
- Experts are usually familiar with the duration of the incubation step from procedures for performing comparable treatment of solid phases in the presence of, e.g. an alcohol and a chaotropic salt as described in the state of the art.
- This step can be optimized by determining the quantity of immobilized nucleic acid on the surface of the solid phase at different points in time. Incubation times of between 10 seconds and 30 minutes can be appropriate for nucleic acids.
- the adsorbed target component is separated from the liquid phase. This may be achieved in general by gravity.
- the separation step is performed by way of applying a magnetic field to the magnetic particles with the adsorbed nucleic acid material.
- the magnetic particles can be pulled to the wall of the vessel in which incubation was performed.
- the liquid containing the sample contents that are not bound to the magnetic particles can then be removed.
- the removal procedure used depends on the type of vessel in which incubation was performed. Suitable steps include removing the liquid via pipetting or aspiration.
- spin columns or “spin filter columns” which are commercially available such as as HIGH PURE TM columns from Roche Diagnostics GmbH Mannheim, Germany.
- Spin filter column tubes usually contain a fleece of non-woven glass fibers located at the bottom of the column and covering the opening at the bottom.
- the adsorption solution containing the nucleic acid is transferred to the column and passed through the fleece by applying force.
- force includes gravitational force and, preferred, centrifugal force.
- spin column very much preferred is the "spin column” procedure wherein the adsorption solution is passed through the filter due to force being applied by way of centrifugation.
- Other ways to pass the adsorption solution through the fleece include the application of pressure or suction.
- the solid phase with the adsorbed nucleic acid may then be washed at least once with a wash solution.
- the washing step or steps is optional.
- a wash solution is used that does not cause the target component to be released from the material surface but that washes away the undesired contaminants as thoroughly as possible.
- This wash step preferably takes place by incubating the material with the bound target nucleic acid(s) with the wash solution.
- the material is preferably resuspended during this step.
- the washing step takes place by rinsing the column with the washing solution.
- the washing solution is passed through the column by applying pressure, suction, centrifugal force or gravitational force.
- Suitable wash solutions are known to the skilled person and may contain a salt, a chaotropic substance and/or an organic solvent such as an alcohol.
- the contaminated wash solution is preferably removed just as in the step described above for adsorbing the nucleic acid to the solid phase.
- the separated material of the solid phase with the adsorbed nucleic acids can be dried briefly in a vacuum, or the fluid can be allowed to evaporate.
- a pretreatment step using acetone may also be performed.
- the conditions are changed to release the nucleic acid from the solid phase.
- This step is also referred to as "eluting" the nucleic acid.
- the solid phase with the immobilized biological material is contacted with an aequous solution with no or only a low amount of chaotropic agent and/ or organic solvent and/or ionic liquid.
- the suspension can be diluted with a solution with no or only a low amount of chaotropic agent and/ or organic solvent and/or ionic liquid.. Buffers of this nature are known to the skilled person, e.g. from DE 37 24 442 and Jakobi, R., et al., Anal. Biochem. 175 (1988) 196-201 .
- the elution buffers with a low salt content are in particular buffers with a content of less than 0.2 mol/l.
- the elution buffer contains the substance Tris for buffering purposes.
- the elution buffer is demineralized water.
- the solution containing the purified nucleic acid can now be used for other reactions.
- the nucleic acid(s) can be precipitated from the solution using, e.g., ethanol or isopropanol. The precipitate can also be subjected to further washing steps. Methods of this kind are well known to the skilled artisan and are described in detail in Sambrook, J., et al., Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press (2001) Cold Spring Harbor, New York .
- another aspect of the invention is a method for isolating a nucleic acid, comprising the following steps (a) providing the following components: (i.) a solid phase capable of reversibly binding nucleic acids; (ii.) sample material containing the nucleic acid; (iii.) a solution containing an ionic liquid comprising an organic cation of Formula I whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group; (iv.) an aqueous buffer; (b) contacting the provided components under conditions suitable for adsorbing the nucleic acid to the solid phase; (c) separating the solid phase with the adsorbed nucleic acid from the solution; (d) eluting the nucleic acid from the solid phase.
- the nucleic acid is DNA and RNA.
- the nucleic acid is DNA.
- the nucleic acid is RNA.
- step (b) is performed under acidic conditions. Even more preferred, step (b) is performed at a pH between 4 and 6.5. Yet, even more preferred, step (b) is performed at a pH between 4.5 and 6.
- RNA to silica matrices can be controlled depending on the concentration of the butylmethylimidazolium cation. This is shown in Figure 4 for yeast RNA. At low butylmethylimidazolium concentrations, i.e. at 1-2M, only low amounts of yeast RNA are adsorbed to the silica matrices. At elevated concentrations, such as 3 M butylmethylimidazolium, the adsorption of yeast RNA to the silica matrix is enhanced.
- Another embodiment of the invention is the use of butylmethylimidazolium tetrafluoroborate for adsorbing RNA to a solid phase, characterized in that the concentration of the ionic liquid is from 1 M to 3 M. It has been found that this concentration range is especially suited to promote the adsorption of RNA to the solid phase, whereas at lower concentrations RNA is bound to a lesser extent (see Figure 4 ).
- a very much preferred embodiment of the invention is a method for adsorbing RNA to a solid phase, characterized in that the method comprises (a) providing the following components: (i.) a solid phase capable of reversibly binding nucleic acids; (ii.) a sample material containing the ribonucleic acid; (iii.) a solution containing a butylmethylimidazolium cation at a concentration from 1 M to 3 M; and (b) contacting the provided components under conditions suitable for adsorbing the ribonucleic acid to the solid phase.
- step (b) is performed under acidic conditions. Even more preferred, step (b) is performed from pH 4 to pH 6.5. Yet, even more preferred, step (b) is performed from pH 4.5 to pH 6. Most preferred, step (b) is performed at pH 6.
- kits Such kits known to the art comprise plasticware useful in the sample preparation procedure. Examples therefor are microwell plates in the 96 or 384 well format or just ordinary reaction tubes manufactured e.g. by Eppendorf, Hamburg, Germany.
- the kits of the invention also comprise some or all other reagents for carrying out the methods according to the invention. Therefore, a kit can additionally contain a solid phase, i.e. a material with an affinity to nucleic acids.
- the solid phase comprises a material with a silica surface.
- the solid phase comprises glass or quartz fibers.
- the solid phase is a composition comprising magnetic glass particles, i.e. magnetically attractable particles coated with glass.
- the kit can further or additionally comprise a lysis buffer containing e.g. a chaotropic agent, a detergent or mixtures thereof.
- a lysis buffer containing e.g. a chaotropic agent, a detergent or mixtures thereof.
- These components of the kit according to the invention may be provided separately in tubes or storage containers. Depending on the nature of the components, these may be even provided in a single tube or storage container.
- the kit may further or additionally comprise a washing solution which is suitable for the washing step of the solid phase where DNA or RNA or both are bound thereto.
- This washing solution may contain an ionic liquid according to the invention and/ or a chaotropic agent in a buffered solution or solutions with an acidic pH. Often the washing solution or other solutions are provided as stock solutions which have to be diluted before use.
- the kit may further or additionally comprise a desorption solution, i.e.
- an elution buffer that is to say a solution for desorbing the nucleic acid from the solid phase.
- a preferred desorption solution can be a buffer (e.g. 10 mM Tris, 1 mM EDTA, pH 8.0) or pure water.
- additional reagents or buffered solutions may be present which can be used for the purification process of a nucleic acid, i.e. DNA or RNA.
- kits for isolating nucleic acid from nucleic acid containing material characterized in that the kit comprises (a) a solid phase capable of reversibly binding nucleic acids; (b) an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all components of the functional group.
- a solid phase capable of reversibly binding nucleic acids
- an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and whereby a delocalized positive charge extends over Y and N, or all
- magnesium(II)chloride and imidazole also can improve the nucleic acid binding mediated by guanidinium such as guanidinium hydrochloride.
- a particular advantage of imidazole as binding enhancer is that it can be used at the same time as buffer salt for adjusting the pH value of the sample solution.
- a further aspect of the invention is a liquid composition for adsorbing a nucleic acid to a solid phase, characterized in that the composition comprises (a) a guanidinium salt and/ or an an ionic liquid comprising an organic cation of Formula I, whereby Y is selected from the group consisting of a carbon atom and a nitrogen atom, whereby X is is selected from the group consisting of a hydrogen atom, a carbon atom and a nitrogen atom, and (b) a compound selected from the group consisting of magnesium(II)chloride, and imidazole.
- the invention also comprises the use of magnesium(II)chloride for adsorbing a nucleic acid to a solid phase from an adsorption solution which comprises the nucleic acid.
- the invention further comprises the use of imidazole for adsorbing a nucleic acid to a solid phase from an adsorption solution which comprises the nucleic acid.
- the present invention comprises a method for isolating a nucleic acid, characterized in that said method comprises the following steps (a) providing the following components: (i) a solid phase capable of reversibly binding nucleic acids; (ii) sample material containing the nucleic acid; (iii) an adsorption solution containing a compound selected from the group consisting of magnesium(II)chloride, and imidazole; (b) contacting the provided components under conditions suitable for adsorbing the nucleic acid to the solid phase; (c) separating the solid phase with the adsorbed nucleic acid from the solution; (d) eluting the nucleic acid from the solid phase.
- Herring sperm DNA (Roche Applied Science, Roche Diagnostics GmbH Mannheim, Cat. No. 10223646) was used in each experiment at a concentration of 120 ⁇ g DNA / 500 ⁇ l.
- Calf thymus DNA (Roche Applied Science, Roche Diagnostics GmbH Mannheim, Id No. 10041785) was used either at 50 ⁇ g or 100 ⁇ g DNA / 500 ⁇ l.
- RNA isolated from baker's yeast using conventional techniques was used in each experiment at a concentration of 79 ⁇ g RNA / 500 ⁇ l.
- Herring sperm DNA was added to the buffers as indicated in Table 1: Table 1 1 1 M guanidinium HCl, 20% ethanol [v/v], 20% [v/v] Triton X-100, 50 mM 2-morpholinoethanesulfonic acid (MES), pH 6 2 1 M guanidinium HCl, 20% [v/v] ethanol, 50 mM MES, pH 6 3 1 M guanidinium HCl, 50 mM MES, pH 6 4 3 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM sodium acetate, pH 4.5 5 1 M 1-butyl-3-methyl-imidazolium octylsulfate, 1 M guanidinium HCl, 50mM MES, pH 6 6 1 M N-(1-butyl)-guanidinium hydrochloride, 50 mM sodium acetate, pH 4.5 7 0.5 M MgCl2, 50
- Calf thymus DNA was used at a concentration of 50 ⁇ g DNA / 500 ⁇ l buffer.
- the DNA was added to the buffers as indicated in Table 2: Table 2 1 1 M guanidinium HCl, 50 mM MES, pH6 2 1 M guanidinium HCl, 10% [v/v] ethanol, 50 mM MES, pH6 3 1 M guanidinium HCl, 20% [v/v] ethanol, 50 mM MES, pH6 4 1 M guanidinium HCl, 40% [v/v] ethanol, 50 mM MES, pH6 5 1 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, pH 4.5 50 mM sodium acetate 6 1 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM MES, pH6 7 1 M N-1-(2-methoxyethyl)-guanidinium hydrochloride, 50
- Calf thymus DNA was used at a concentration of 100 ⁇ g DNA / 500 ⁇ l buffer.
- the DNA was added to the buffers as indicated in Table 3: Table 3 1 1 M guanidinium HCl, 50 mM MES, pH6 2 1 M guanidinium HCl, 10% [v/v] ethanol, 50 mM MES, pH6 3 1 M guanidinium HCl, 20% [v/v] ethanol, 50 mM MES, pH6 4 1 M guanidinium HCl, 40% [v/v] ethanol, 50 mM MES, pH6 5 1 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM sodium acetate, pH 4.5 6 1 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM MES, pH6
- RNA (see Example 1) was used at a concentration of 79 ⁇ g RNA / 500 ⁇ l buffer. The RNA was added to the buffers as indicated in Table 4: Table 4 1 1 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM sodium acetate, pH 4.5 2 2 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM MES, pH6 3 3 M 1-butyl-3-methyl-imidazolium tetrafluoroborate, 50 mM MES, pH6
- the magnetic particles were used from a MagNA Pure LC DNA isolation kit - large volume- from Roche Applied Science, Roche Diagnostics GmbH Mannheim, Cat. No. 03310515. The particles were suspended in isopropanol (60 mg/ml).
- Calf thymus DNA was used at a concentration of 50 ⁇ g DNA / 500 ⁇ l buffer. The DNA was added to the buffers as indicated in Table 5. Each sample was mixed with 100 ⁇ l of the particle suspension for 30 sec at room temperature.
- the particles were immobilized by means of a magnetic field and separated from the liquid phase.
- the particles were washed once with 500 ⁇ l of a first aqueous washing buffer consisting of 5 M guanidinium HCl, 38% [v/v] ethanol, 20 mM Tris HCl, pH 6.6 and twice with 500 ⁇ l of a second aqueous washing buffer consisting of 100 mM NaCl, 50% [v/v] ethanol, 10 mM Tris HCl, pH 7.4.
- Each wash was performed by removing the magnetic field followed by suspending the particles in the respective wash buffer.
- the particles were immobilized again by means of a magnetic field and separated from the liquid phase.
- adsorbed DNA was eluted from the particles by adding to the particles 500 ⁇ l elution buffer (10 mM Tris HCl, pH 8 in water) and agitating the particles in the elution buffer by vortexing vigorously. Subsequently, the particles were sedimented by centrifugation and the DNA-containing supernatant was recovered.
- 500 ⁇ l elution buffer (10 mM Tris HCl, pH 8 in water
- a sample 100 ⁇ l was taken from each eluate and, a 1:10 dilution was made with water, and the nucleic acid concentration was determined by measuring the extinction at 260 nm wavelength.
- Table 5 indicates the compositions of the adsorption buffers used as well as the amount of DNA (in ⁇ g) eluted from the particles in each experiment.
- Table 5 buffer composition DNA (in ⁇ g) 1 4.5 M guanidinium thiocyanate, 20% [v/v] Triton X-100, 50 mM Tris HCl, pH 6, 0.1% (w/v) bromophenol blue 35.8 2 4.5 M guanidinium thiocyanate, 50 mM Tris HCl, pH 6 3.5 3 4.5 M guanidinium thiocyanate, 1 M 1-butyl-3-methylimidazolium tetrafluoroborate, 50 mM Tris HCl, pH 6 24 4 4.5 M guanidinium thiocyanate, 0.1 M 1-butyl-3-methylimidazolium tetrafluoroborate, 50 mM Tris HCl, pH 6 1.5 5 1 M guanidinium thiocyanate,
- a solution containing Calf thymus DNA was prepared according to Example 1.
- the DNA was adsorbed onto glass fleece in the presence of an ionic liquid or guanidinium thiocyanate.
- the substances which were tested are listed in Table 6.
- Each adsorption solution was buffered to a pH value of pH 6 using MES, Tris or acetate buffer (10-50 mM).
- Adsorption was effected by passing the adsorption solution through the glass fleece of a spin column, e.g. a HIGHPURE TM spin column. Amounts of 25 ⁇ g, 50 ⁇ g and 100 ⁇ g were applied.
- DNA was quantified spectrophotometrically (a) before applying the adsorption solution to the spin columns and (b) in the flow-through after the adsorption solution was passed through the glass fleece.
- the concentration of DNA in the adsorption solution was determined prior to the adsorption step using the PICO GREEN assay (Invitrogen, Cat. No. P7589). Furthermore, using the PICO GREEN assay, the residual DNA concentration in each adsorption buffer after being passed through the glass fleece (that is: after the adsorption step) was determined. Using these measurements, the relative amount of DNA bound to the solid phase was determined for each adsorption solution.
- the DNA concentration in the eluate was determined, however using photometric determination at 260 nm.
- the amount of nucleic acid adsorbed to the solid phase was determined by subtracting the nucleic acid concentration in the flow-through (i.e. after adsorption) from the nucleic acid concentration initially applied to the column.
- Table 6 substance conc. in adsorption solution amount of DNA applied to glass fleece ( ⁇ g) amount of DNA bound to glass fleece ( ⁇ g) amount of DNA in flow-through ( ⁇ g) guanidinium thiocyanate 1 M 100 83,69.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08007550.0A EP1983051B1 (fr) | 2007-04-20 | 2008-04-18 | Isolation et purification de molécules d'acide nucléique avec une phase solide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07008073 | 2007-04-20 | ||
EP08007550.0A EP1983051B1 (fr) | 2007-04-20 | 2008-04-18 | Isolation et purification de molécules d'acide nucléique avec une phase solide |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1983051A2 true EP1983051A2 (fr) | 2008-10-22 |
EP1983051A3 EP1983051A3 (fr) | 2008-12-03 |
EP1983051B1 EP1983051B1 (fr) | 2014-11-26 |
Family
ID=38290130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08007550.0A Active EP1983051B1 (fr) | 2007-04-20 | 2008-04-18 | Isolation et purification de molécules d'acide nucléique avec une phase solide |
Country Status (6)
Country | Link |
---|---|
US (1) | US8101744B2 (fr) |
EP (1) | EP1983051B1 (fr) |
JP (2) | JP5325448B2 (fr) |
CN (1) | CN101289661B (fr) |
CA (1) | CA2629589C (fr) |
HK (1) | HK1125672A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2302030A1 (fr) | 2009-09-02 | 2011-03-30 | Roche Diagnostics GmbH | Réactifs pour la lyse de cellules bactériennes |
WO2011083076A1 (fr) * | 2010-01-08 | 2011-07-14 | Roche Diagnostics Gmbh | Récupération améliorée d'acides nucléiques à partir de particules de verre magnétiques |
EP2771462A1 (fr) * | 2011-10-27 | 2014-09-03 | GE Healthcare Bio-Sciences AB | Purification d'un acide nucléique |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121888A2 (fr) * | 2005-05-06 | 2006-11-16 | Gen-Probe Incorporated | Procedes de capture d'acide nucleique cible |
US10316352B2 (en) | 2008-05-13 | 2019-06-11 | Gen-Probe Incorporated | Methods of capturing a target nucleic acid for amplification and detection using an inactivatable target capture oligomer |
JP5827948B2 (ja) * | 2009-08-17 | 2015-12-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | ウイルスを単離する方法 |
BR112012031267A2 (pt) | 2010-07-07 | 2015-10-13 | Diagon Kft | procedimento para o isolamento específico do conteúdo de dna integral dos germes bacterianos e kit essa finalidade |
US20150045232A1 (en) * | 2010-12-28 | 2015-02-12 | Bexmart | Integrated and versatile methods for systems diagnosis of diseases |
CN102533725A (zh) * | 2011-09-09 | 2012-07-04 | 上海佑科生物技术有限公司 | 一体化缓冲液及使用该一体化缓冲液分离核酸的方法 |
GB201303666D0 (en) * | 2013-03-01 | 2013-04-17 | Goldsborough Andrew S | Sample fixation and stabilisation |
CA2940526A1 (fr) | 2014-01-28 | 2015-08-06 | Dice Molecules Sv, Llc | Monolithes a composes de reconnaissance attaches, reseaux associes et utilisations associees |
JP2016020826A (ja) * | 2014-07-14 | 2016-02-04 | 山善株式会社 | 分取液体クロマトフラフィ用インジェクタ |
WO2018156906A1 (fr) * | 2017-02-27 | 2018-08-30 | miDiagnostics NV | Système et procédé de purification et d'amplification d'acides nucléiques |
US20230183674A1 (en) * | 2020-05-25 | 2023-06-15 | Sekisui Medical Co., Ltd. | Method for purifying nucleic acid |
CN114573483B (zh) * | 2022-03-16 | 2022-11-01 | 湖南师范大学 | 一种疏水的磁性离子液体及其制备方法和应用 |
CN114990109A (zh) * | 2022-06-21 | 2022-09-02 | 中国科学院过程工程研究所 | 一种核糖核酸纯化伴侣及其应用 |
CN115960885B (zh) * | 2022-10-09 | 2023-12-12 | 南京诺唯赞生物科技股份有限公司 | 一种提取肝素钠样品中核酸的方法及组合物 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
EP0281390A2 (fr) | 1987-03-02 | 1988-09-07 | Gen-Probe Incorporated | Supports polycationiques pour la purification, la séparation et l'hybridation d'acide nucléique |
DE3724442A1 (de) | 1987-07-23 | 1989-02-02 | Europ Lab Molekularbiolog | Verfahren und vorrichtung zur reinigung von m-13-phagen-dna |
WO1990001069A1 (fr) | 1988-07-20 | 1990-02-08 | Segev Diagnostics, Inc. | Procede d'amplification et de detection de sequences d'acide nucleique |
EP0439182A2 (fr) | 1990-01-26 | 1991-07-31 | Abbott Laboratories | Procédé amélioré pour amplifier d'acides nucléiques cibles applicable à la réaction en chaîne de polymérase et ligase |
WO1992000880A1 (fr) | 1990-07-09 | 1992-01-23 | S.C.I. Operations Pty Limited Trading As Smorgon Plastics | Recipient ameliore |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
EP0818461A2 (fr) | 1996-07-12 | 1998-01-14 | Toyo Boseki Kabushiki Kaisha | Procédé pour isoler des acides ribonucléiques. |
US5808041A (en) | 1993-08-30 | 1998-09-15 | Promega Corporation | Nucleic acid purification using silica gel and glass particles |
WO1999061603A1 (fr) | 1998-05-27 | 1999-12-02 | Qiagen Gmbh | Procede simple et rapide d'isolement d'acides nucleiques circulaires |
WO2000069872A2 (fr) | 1999-05-14 | 2000-11-23 | Promega Corporation | MATRICE ECHANGEUSE D'IONS DEPENDANT DU pH, UTILISEE POUR ISOLER DES ACIDES NUCLEIQUES |
WO2001094573A2 (fr) | 2000-06-02 | 2001-12-13 | Pall Corporation | Traitement de fluides contenant des plasmides |
WO2002048164A2 (fr) | 2000-12-14 | 2002-06-20 | Dna Research Innovations Limited | Isolement d'acides nucleiques |
US20040121336A1 (en) | 2002-12-20 | 2004-06-24 | Greenfield I Lawrence | Method for generating multiple samples containing a predetermined amount of nucleic acid |
US20040180445A1 (en) | 2003-03-12 | 2004-09-16 | Domanico Michael J. | Methods and compositions for purification of nucleic acid from a host cell |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8900725A (nl) * | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
GB9425138D0 (en) * | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
CA2318306A1 (fr) | 1997-12-06 | 1999-06-17 | Dna Research Instruments Limited | Isolement d'acides nucleiques |
GB9725839D0 (en) * | 1997-12-06 | 1998-02-04 | Baker Matthew J | Isolation of nucleic acids |
US6858720B2 (en) * | 2001-10-31 | 2005-02-22 | Agilent Technologies, Inc. | Method of synthesizing polynucleotides using ionic liquids |
WO2005064010A1 (fr) | 2003-12-19 | 2005-07-14 | Preanalytix Gmbh | Composition permettant de lier un acide nucléique à une phase solide |
MXPA05001815A (es) * | 2004-02-20 | 2005-08-24 | Hoffmann La Roche | Adsorcion de acidos nucleicos a una fase solida. |
US20070196826A1 (en) | 2004-03-23 | 2007-08-23 | Hiroyuki Ohno | Solvent For Dissolving Nucleic Acid, Nucleic Acid-Containing Solution And Method Of Preserving Nucleic Acid |
WO2007094739A1 (fr) * | 2006-02-13 | 2007-08-23 | Agency For Science, Technology And Research | Procédé de traitement d'un échantillon biologique et/ou chimique |
-
2008
- 2008-04-16 CA CA2629589A patent/CA2629589C/fr active Active
- 2008-04-17 JP JP2008107526A patent/JP5325448B2/ja active Active
- 2008-04-18 US US12/105,556 patent/US8101744B2/en active Active
- 2008-04-18 EP EP08007550.0A patent/EP1983051B1/fr active Active
- 2008-04-18 CN CN200810092951.0A patent/CN101289661B/zh active Active
-
2009
- 2009-04-15 HK HK09103475.9A patent/HK1125672A1/xx unknown
-
2012
- 2012-08-10 JP JP2012178156A patent/JP5685227B2/ja active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195B1 (fr) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
EP0281390A2 (fr) | 1987-03-02 | 1988-09-07 | Gen-Probe Incorporated | Supports polycationiques pour la purification, la séparation et l'hybridation d'acide nucléique |
DE3724442A1 (de) | 1987-07-23 | 1989-02-02 | Europ Lab Molekularbiolog | Verfahren und vorrichtung zur reinigung von m-13-phagen-dna |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
WO1990001069A1 (fr) | 1988-07-20 | 1990-02-08 | Segev Diagnostics, Inc. | Procede d'amplification et de detection de sequences d'acide nucleique |
EP0439182A2 (fr) | 1990-01-26 | 1991-07-31 | Abbott Laboratories | Procédé amélioré pour amplifier d'acides nucléiques cibles applicable à la réaction en chaîne de polymérase et ligase |
WO1992000880A1 (fr) | 1990-07-09 | 1992-01-23 | S.C.I. Operations Pty Limited Trading As Smorgon Plastics | Recipient ameliore |
US5808041A (en) | 1993-08-30 | 1998-09-15 | Promega Corporation | Nucleic acid purification using silica gel and glass particles |
EP0818461A2 (fr) | 1996-07-12 | 1998-01-14 | Toyo Boseki Kabushiki Kaisha | Procédé pour isoler des acides ribonucléiques. |
WO1999061603A1 (fr) | 1998-05-27 | 1999-12-02 | Qiagen Gmbh | Procede simple et rapide d'isolement d'acides nucleiques circulaires |
WO2000069872A2 (fr) | 1999-05-14 | 2000-11-23 | Promega Corporation | MATRICE ECHANGEUSE D'IONS DEPENDANT DU pH, UTILISEE POUR ISOLER DES ACIDES NUCLEIQUES |
WO2001094573A2 (fr) | 2000-06-02 | 2001-12-13 | Pall Corporation | Traitement de fluides contenant des plasmides |
WO2002048164A2 (fr) | 2000-12-14 | 2002-06-20 | Dna Research Innovations Limited | Isolement d'acides nucleiques |
US20040121336A1 (en) | 2002-12-20 | 2004-06-24 | Greenfield I Lawrence | Method for generating multiple samples containing a predetermined amount of nucleic acid |
US20040180445A1 (en) | 2003-03-12 | 2004-09-16 | Domanico Michael J. | Methods and compositions for purification of nucleic acid from a host cell |
Non-Patent Citations (19)
Title |
---|
ABRAMSON, R., D.; MYERS, T., W., CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, 1993, pages 41 - 47 |
BARANY, F., PCR METHODS AND APPL., vol. 1, 1991, pages 5 - 16 |
BARANY, F., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 189 - 193 |
BOOM, R. ET AL., J. CLIN. MICROBIOL., vol. 28, 1990, pages 495 - 503 |
CHOMCZYNSKI, P.; SACCHI, N., ANAL. BIOCHEM., vol. 162, 1987, pages 156 - 159 |
DANDLIKER, W., B.; DE SAUSSURE, V., A.: "The Chemistry of Biosurfaces", 1971, MARCEL DEKKER, INC., pages: 18 |
DORE, K. ET AL., J. AM. CHEM. SOC., vol. 126, 2004, pages 4240 - 4244 |
GUATELLI, J., C. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1874 - 1878 |
JAKOBI, R. ET AL., ANAL. BIOCHEM., vol. 175, 1988, pages 196 - 201 |
KWOH, D., Y. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 1173 - 1177 |
LCR, WU, D., Y.; WALLACE, R., B., GENOMICS, vol. 4, 1989, pages 560 - 569 |
MARKO, M., A. ET AL., ANAL. BIOCHEM., vol. 121, 1982, pages 382 - 387 |
MELZAK, K., A. ET AL., J. COLL. INTERF. SCI., vol. 181, 1996, pages 635 - 644 |
SAMBROOK, J. ET AL.: "Molecular Cloning, A Laboratory Manual", 2001, CSHL PRESS |
SCHEIT, K., H.: "Nucleotide Analogs", 1980, JOHN WILEY AND SONS |
STEWART, K., D. ET AL., J. PHYS. ORG. CHEM., vol. 5, 1992, pages 461 - 466 |
UHLMANN, E.; PEYMAN, A., CHEM. REV., vol. 90, 1990, pages 543 - 584 |
VOGELSTEIN, B.; GILLESPIE, D., PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 615 - 619 |
WHELEN, A., C.; PERSING, D., H., ANNU. REV. MICROBIOL., vol. 50, 1996, pages 349 - 373 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2302030A1 (fr) | 2009-09-02 | 2011-03-30 | Roche Diagnostics GmbH | Réactifs pour la lyse de cellules bactériennes |
US9371509B2 (en) | 2009-09-02 | 2016-06-21 | Roche Diagnostics Operations, Inc. | Reagents for lysis of bacterial cells |
WO2011083076A1 (fr) * | 2010-01-08 | 2011-07-14 | Roche Diagnostics Gmbh | Récupération améliorée d'acides nucléiques à partir de particules de verre magnétiques |
US8420801B2 (en) | 2010-01-08 | 2013-04-16 | Roche Molecular Systems, Inc. | Recovery of nucleic acids from magnetic glass particles |
EP2771462A1 (fr) * | 2011-10-27 | 2014-09-03 | GE Healthcare Bio-Sciences AB | Purification d'un acide nucléique |
EP2771462A4 (fr) * | 2011-10-27 | 2015-04-08 | Ge Healthcare Bio Sciences Ab | Purification d'un acide nucléique |
US9340828B2 (en) | 2011-10-27 | 2016-05-17 | Ge Healthcare Bio-Sciences Ab | Purification of nucleic acid |
Also Published As
Publication number | Publication date |
---|---|
US20080319182A1 (en) | 2008-12-25 |
CN101289661A (zh) | 2008-10-22 |
US8101744B2 (en) | 2012-01-24 |
JP2008263982A (ja) | 2008-11-06 |
CA2629589C (fr) | 2016-03-29 |
JP5685227B2 (ja) | 2015-03-18 |
CA2629589A1 (fr) | 2008-10-20 |
JP5325448B2 (ja) | 2013-10-23 |
EP1983051A3 (fr) | 2008-12-03 |
HK1125672A1 (en) | 2009-08-14 |
CN101289661B (zh) | 2013-08-21 |
EP1983051B1 (fr) | 2014-11-26 |
JP2012255798A (ja) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1983051B1 (fr) | Isolation et purification de molécules d'acide nucléique avec une phase solide | |
US7329491B2 (en) | Methods for isolating nucleic acids | |
EP2217703B1 (fr) | Procédé d'isolation d'adn génomique, d'arn et de protéines, à partir d'un échantillon unique | |
EP2094846B1 (fr) | Utilisation de tde pour l'isolement d'acides nucléiques | |
JP2002502856A (ja) | 核酸の単離および精製方法 | |
JPH10501246A (ja) | 極度に少量でかつ非常に強く汚染された非常に種々の出発物質から核酸を単離および精製する一般的方法 | |
US8648187B2 (en) | Method for separation of double-stranded and single-stranded nucleic acids from the same sample | |
EP2521779B1 (fr) | Récupération améliorée d'acides nucléiques à partir de particules de verre magnétiques | |
EP1529840A1 (fr) | Procédé rapide et économique pour l'isolement d' acides nucléiques | |
US8062843B2 (en) | Use of acetals for isolation of nucleic acids | |
EP1992693B1 (fr) | Adsorption d'acides nucléiques sur des phases solides dans des conditions de faible teneur en sel | |
EP2647709B1 (fr) | Composés d'amine pour la préparation sélective d'échantillons biologiques | |
EP1524317B1 (fr) | Procédé pour l'isolation d'acides nucléiques | |
US20110046361A1 (en) | Method for separation of double-stranded and single-stranded nucleic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17P | Request for examination filed |
Effective date: 20090603 |
|
17Q | First examination report despatched |
Effective date: 20090625 |
|
AKX | Designation fees paid |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140708 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 698236 Country of ref document: AT Kind code of ref document: T Effective date: 20141215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008035538 Country of ref document: DE Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 698236 Country of ref document: AT Kind code of ref document: T Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150226 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150326 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150326 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008035538 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20150827 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150418 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080418 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141126 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240320 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240320 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240320 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240501 Year of fee payment: 17 |